Nasdaq:US$17.45 (-0.03) | HKEX:HK$26.70 (-0.68) | AIM:£2.64 (+0.1)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer